Specialized news

Array ( [0] => stdClass Object ( [id] => 1415 [id_crawler] => [category_product] => NULL [thumbnail] => 800x600-web.png [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 1 [displayed_time] => 2026-03-13 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2026-03-13 14:02:45 [updated_time] => 2026-03-13 14:06:08 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-launches-PGT-FAST-Embryo-genetic-screening-solution-with-outstanding-turnaround-time [title] => Eurofins GENTIS launches PGT-FAST – Embryo genetic screening solution with outstanding turnaround time [description] => In recent years, advancements in assisted reproductive technologies have provided the opportunity for millions of couples worldwide to become parents. However, beyond creating embryos through in vitro fertilization (IVF), selecting embryos with good genetic quality remains a crucial factor in achieving successful pregnancies. Numerous studies have shown that chromosomal abnormalities in embryos are among the common causes of implantation failure, early miscarriage, or genetic syndromes in children after birth. Therefore, preimplantation genetic testing (PGT) has become increasingly important in modern IVF procedures. To support fertility centers in optimizing embryo selection, Eurofins GENTIS has launched a new test, PGT-FAST – an embryo genetic screening solution with the outstanding advantage of delivering results in just 15 hours. [content] =>

Comprehensive Chromosome Analysis for Embryo Genetic Screening
PGT-FAST is a preimplantation genetic test performed before embryo transfer during IVF. By analyzing embryonic cells, the test evaluates the chromosomal status of embryos and detects abnormalities that may affect pregnancy development. The test allows for the analysis of all 24 chromosomes in the embryo, identifying numerical chromosomal abnormalities, also known as aneuploidy. These abnormalities can lead to serious genetic syndromes or prevent normal embryo development.

In addition, PGT-FAST can detect large structural chromosomal abnormalities, such as deletions or duplications of 5Mb or larger. These abnormalities may be associated with genetic syndromes that impact the health and development of the child. Embryo genetic screening provides fertility specialists with scientific evidence to select embryos with normal chromosomal complements, thereby increasing implantation rates and improving IVF treatment outcomes.

Significantly Reduced Turnaround Time
One of the most notable features of PGT-FAST is its ability to significantly shorten analysis and reporting time. The optimized process allows results to be delivered within 15 hours from sample analysis. Rapid turnaround time offers practical benefits for both fertility centers and patients. Physicians can access embryo genetic results more quickly, enabling timely and appropriate clinical decisions during treatment. For many couples undergoing IVF, a shorter waiting period also helps reduce psychological stress and provides greater control over their treatment plan.

Application of Next-Generation Sequencing Technology
PGT-FAST is based on Next Generation Sequencing (NGS), one of the most advanced and accurate genetic analysis technologies available today. The sequencing system used in this test is based on the Illumina platform (USA), combined with specialized genetic data analysis software, enabling highly accurate detection of abnormalities. The test achieves high sensitivity and specificity, ensuring reliable results for embryo genetic analysis. Utilizing modern analytical technologies not only improves test accuracy but also optimizes processes and reduces turnaround time.

The introduction of PGT-FAST represents another step forward in expanding Eurofins GENTIS’ genetic testing ecosystem in the field of assisted reproduction. This new testing solution is expected to provide fast, accurate, and efficient options for IVF centers and families seeking the opportunity to welcome healthy babies.

In an era where reproductive medicine increasingly emphasizes genetic factors, the development of advanced testing solutions like PGT-FAST is expected to further enhance treatment quality and help families move closer to their dream of becoming parents.

[content_more] => [meta_title] => Eurofins GENTIS launches PGT-FAST – Embryo genetic screening solution with outstanding turnaround ti [meta_description] => To support fertility centers in optimizing embryo selection, Eurofins GENTIS has launched a new test, PGT-FAST – an embryo genetic screening solution with the outstanding advantage of delivering results in just 15 hours. [meta_keyword] => GENTIS,PGT-FAST [thumbnail_alt] => [post_id] => 1415 [category_id] => 15 ) [1] => stdClass Object ( [id] => 1414 [id_crawler] => [category_product] => NULL [thumbnail] => z7616146207741_e7cffc3f616d1b8d7390f14ae1bddc50.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 1 [displayed_time] => 2026-03-13 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2026-03-13 13:33:19 [updated_time] => 2026-03-13 16:35:38 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-updates-PGT-FAST-and-GEN28-tests-at-Hanoi-General-Hospital-IVF-center [title] => Eurofins GENTIS updates PGT-FAST and GEN28 tests at Hanoi General Hospital IVF center [description] => Recently, a delegation of experts from Eurofins GENTIS, led by Dr. Nguyen Quang Vinh (Director of Eurofins GENTIS Testing Center), held a professional working session with the doctors and nurses of the Hanoi General Hospital Assisted Reproduction Center. This collaboration aims to update the latest advances in genetic testing, thereby contributing to improved treatment outcomes for families facing infertility. The session also opened opportunities for academic exchange and laid the groundwork for deeper cooperation between the two units in the future. [content] =>

The Eurofins GENTIS delegation was welcomed by MSc. MD. Nguyen Duy Phuong – Director of the Assisted Reproduction and Gender Medicine Center, along with doctors, nurses, and technicians from the hospital.

During the session, Pharmacist Duong Thi Phuong (Product Management Specialist at Eurofins GENTIS) presented an overview of PGT-FAST, the most advanced pre-implantation genetic screening test currently developed by Eurofins GENTIS. PGT-FAST is a pre-implantation genetic test performed before embryo transfer in the IVF process, helping assisted reproduction centers select embryos with high genetic quality. The test analyzes embryonic cells to assess genetic status and surveys all 24 chromosomes to detect chromosomal abnormalities (aneuploidy) – a common cause of implantation failure, early miscarriage, or genetic syndromes in newborns.

In addition, PGT-FAST can detect large structural chromosomal abnormalities such as deletions or duplications of 5Mb or more. The test is implemented using next-generation sequencing (NGS) technology on the Illumina platform, combined with advanced genetic data analysis software, ensuring high sensitivity, specificity, and accuracy in embryo genetic analysis.

A notable advantage of PGT-FAST is its rapid turnaround time, taking only about 15 hours from sample analysis to result. This allows doctors to access embryo genetic results quickly and make timely clinical decisions during the IVF cycle.

Alongside PGT-FAST, Pharmacist Phuong also introduced GEN28, a screening service for carriers of common genetic diseases. GEN28 screens 28 severe recessive genetic disease genes, detecting carriers even if they are completely healthy. The test uses NGS technology combined with advanced bioinformatics analysis to identify gene variants that may be passed to the next generation. With only 2–3 ml of whole blood, GEN28 can screen 28 genes associated with 25 genetic diseases and syndromes, including Thalassemia, G6PD deficiency, cystic fibrosis, Tay–Sachs disease, Wilson disease, galactose metabolism disorders, and more. These conditions can have serious, long-term impacts on health and quality of life.

Information on PGT-FAST and GEN28 received great attention from the medical team at Hanoi General Hospital IVF Center. Dr. Nguyen Quang Vinh directly answered many professional questions from the doctors. Additionally, Dr. Vinh emphasized Eurofins GENTIS’s commitment to continue applying advanced testing technologies and strengthening collaboration with assisted reproduction centers to improve patient service quality. At the conclusion of the session, MSc. MD. Nguyen Duy Phuong praised the expert team’s professional sharing and expressed the hope that both parties will continue to enhance cooperation in the future to provide more effective reproductive solutions for patients.

The session ended in an open and collaborative atmosphere. This event reaffirms Eurofins GENTIS’s commitment to delivering modern, accurate, and effective genetic testing solutions, contributing to increased opportunities for many Vietnamese families to become parents.

[content_more] => [meta_title] => Eurofins GENTIS updates PGT-FAST and GEN28 tests at Hanoi General Hospital IVF center [meta_description] => center Recently, a delegation of experts from Eurofins GENTIS, led by Dr. Nguyen Quang Vinh (Director of Eurofins GENTIS Testing Center), held a professional working session with the doctors and nurses of the Hanoi General Hospital Assisted Reproduction [meta_keyword] => GENTIS,PGT-FAST,GEN28 [thumbnail_alt] => [post_id] => 1414 [category_id] => 15 ) [2] => stdClass Object ( [id] => 1408 [id_crawler] => [category_product] => NULL [thumbnail] => c297db27af2f2171783e.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2026-02-06 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2026-02-06 09:54:55 [updated_time] => 2026-02-27 13:51:10 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Summary-of-5-hereditary-cancer-testing-packages-at-Eurofins-GENTIS [title] => Summary of 5 hereditary cancer testing packages at Eurofins GENTIS [description] => Cancer is one of the leading causes of death worldwide. Numerous studies indicate that 5–10% of cancer cases are associated with hereditary factors, resulting from gene mutations that can be passed down from one generation to the next. Hereditary cancer testing helps identify risks early, enabling the development of appropriate monitoring, prevention, and medical intervention strategies. [content] =>

Understanding the growing demand for genetic screening in the community, Eurofins GENTIS has developed five hereditary cancer testing packages ranging from basic to advanced levels, tailored to different individuals, age groups, and family histories.

Why consider hereditary cancer testing?

Unlike conventional tests that detect cancer after it develops, hereditary cancer testing focuses on genetic analysis to determine cancer risk before clinical symptoms appear.

Key benefits include:

Early detection of potential hereditary cancer risks
Proactive development of personalized screening plans
Support for physicians in prevention and treatment counseling
Provision of valuable genetic information for family members
Reduced psychological burden through better understanding of personal health risks

With internationally standardized laboratories and an experienced team of genetic experts, Eurofins GENTIS delivers accurate, reliable testing solutions tailored to the Vietnamese population.

Summary of 5 hereditary cancer testing packages at Eurofins GENTIS

LADY - CARE: Hereditary cancer testing package for women

LADY - CARE is specifically designed for women, focusing on cancers with high incidence rates and strong hereditary associations.

Analysis of 10 genes
Screening for hereditary breast cancer, ovarian cancer, and colorectal cancer

Suitable for:

Women with a family history of breast, ovarian, or colorectal cancer
Women who wish to proactively assess hereditary cancer risk
Women of reproductive or middle age

LADY - CARE helps women better understand their genetic risks and develop appropriate medical monitoring and intervention plans to enhance quality of life.

MEN - CARE: Hereditary cancer screening solution for Men

Men also face various cancers influenced by hereditary factors, particularly prostate and gastrointestinal cancers.

Analysis of 10 genes
Screening for hereditary prostate cancer, colorectal cancer, and gastric cancer

Suitable for:

Men with a family history of related cancers
Middle-aged men or those with high-risk lifestyles or environmental exposures
Individuals seeking proactive genetic health screening

MEN - CARE is an important step in early cancer risk detection, enabling long-term prevention and medical follow-up.

PRE - CARE: Expanded screening for 15 hereditary cancers

PRE - CARE is an extended hereditary cancer testing package for individuals seeking more comprehensive risk assessment.

Analysis of mutations in 17 genes
Screening for 15 hereditary cancers, including: lung, stomach, breast, ovarian, colorectal, pancreatic, kidney, prostate, thyroid, skin, endometrial cancers, paraganglioma, retinoblastoma, pheochromocytoma, and multiple endocrine neoplasia

Suitable for:

Individuals with family histories of multiple cancer types
Those seeking expanded hereditary cancer screening
Individuals planning marriage or childbirth

PRO - CARE: Advanced hereditary cancer testing package

PRO - CARE provides a comprehensive overview of hereditary cancer risks.

Analysis of mutations in 133 genes
Screening for 30 hereditary cancers, including: lung, stomach, breast, ovarian, colorectal, pancreatic, kidney, prostate, thyroid, skin, endometrial, liver, bladder, head and neck, esophageal, biliary tract, small intestine, brain, bone, parathyroid cancers; acute leukemia (blood cancer); rhabdomyosarcoma; pituitary adenoma; neuroblastoma; neurofibroma; and multiple myeloma

Suitable for:

Individuals at high risk of cancer
Families with multiple affected members
Those requiring comprehensive genetic evaluation for long-term monitoring

DIAMOND - CARE: The most comprehensive genetic testing package

DIAMOND - CARE is the most advanced and comprehensive package at Eurofins GENTIS, combining hereditary cancer screening with inherited chronic disease testing.

Total analysis of 177 genes associated with 69 hereditary chronic diseases and cancers, including:

10 genes – 9 common autosomal recessive disorders:
Alpha Thalassemia, Beta Thalassemia, G6PD deficiency, Phenylketonuria (PKU), Galactose metabolism disorder, Citrin deficiency–related cholestasis, 5-Alpha Reductase deficiency–related male sex development disorder, Pompe disease, Wilson disease
133 genes – Screening for 30 hereditary cancers (entire PRO - CARE panel)
34 genes – 30 hereditary syndromes and chronic conditions:
20 cardiovascular diseases, 5 connective tissue disorders, and 5 endocrine–metabolic disorders

DIAMOND - CARE is especially suitable for individuals seeking a comprehensive evaluation of hereditary health risks for themselves and their families.

With advanced gene sequencing technology, strict quality control processes, and a highly experienced team of experts, Eurofins GENTIS is committed to delivering accurate, reliable, and clinically valuable results.

Hereditary cancer testing is not just a test — it is a proactive step toward early prevention, appropriate monitoring, and personalized healthcare.

Contact Eurofins GENTIS via hotline 1800 2010 for detailed consultation and to choose the most suitable testing package for you and your family.

[content_more] => [meta_title] => Summary of 5 hereditary cancer testing packages at Eurofins GENTIS [meta_description] => Cancer is one of the leading causes of death worldwide. Numerous studies indicate that 5–10% of cancer cases are associated with hereditary factors, resulting from gene mutations that can be passed down from one generation to the next. Hereditary cancer t [meta_keyword] => GENTIS,genetic disorder [thumbnail_alt] => [post_id] => 1408 [category_id] => 15 ) [3] => stdClass Object ( [id] => 1405 [id_crawler] => [category_product] => NULL [thumbnail] => z7475342255361_6d2a37fa1d1528705dc55057db6a4222.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 1 [displayed_time] => 0000-00-00 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2026-01-29 13:20:52 [updated_time] => 2026-01-30 13:30:18 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-and-Phenikaa-hospital-strengthen-professional-exchange-on-preimplantation-genetic-testing [title] => Eurofins GENTIS and Phenikaa hospital strengthen professional exchange on preimplantation genetic testing [description] => In recent years, alongside in vitro fertilization (IVF), preimplantation genetic testing (PGT) solutions have increasingly been recognized as a key factor in improving success rates, minimizing risks, and working toward the goal of delivering healthy babies. Scientifically guided embryo selection plays a crucial role in helping clinicians and patients make safer and more effective decisions in each treatment cycle. [content] =>

Responding to the growing demand for the application of PGT solutions in assisted reproduction, Eurofins GENTIS recently collaborated with Phenikaa Hospital to organize a professional working session. The meeting focused on exchanging insights and updating advanced genetic testing solutions currently applied in reproductive medicine, including specialized technologies and services developed and implemented by Eurofins GENTIS.

Representing Eurofins GENTIS, Dr. Nguyen Quang Vinh (Laboratory Director) directly presented and reported on the professional content at the session. On the Phenikaa Hospital side, the meeting was attended by a team of physicians, specialists, and technicians in assisted reproduction, who engaged in in-depth discussions on the practical application of genetic testing in IVF treatment.

At the meeting, Dr. Vinh provided an overview of the PGT testing system currently implemented at Eurofins GENTIS, with a focus on PGT-A/SR—preimplantation genetic testing for aneuploidies and structural rearrangements. PGT-A/SR enables comprehensive analysis of all 24 chromosomes, detecting numerical and structural abnormalities, including aneuploidy, deletions, duplications, and mosaicism. The application of PGT-A/SR helps IVF clinicians select embryos with higher implantation potential, reduce the risk of early miscarriage, and increase embryo transfer success rates, particularly in advanced-age patients, those with repeated IVF failures, or a history of pregnancy loss. Data shared by Eurofins GENTIS showed that embryos with chromosomal abnormalities account for nearly half of all analyzed samples. This highlights the importance of preimplantation genetic testing, as many embryos with good morphology may still harbor underlying genetic abnormalities that can directly affect pregnancy outcomes if not screened early.

In addition to PGT-A/SR, PGT-M was another topic of particular interest to Phenikaa Hospital. This solution is designed for couples who carry genes associated with inherited diseases but wish to have healthy children free from these conditions. Eurofins GENTIS has currently implemented more than 100 PGT-M protocols for a wide range of conditions such as thalassemia, spinal muscular atrophy (SMA), hemophilia, and other rare genetic disorders, using advanced technologies including next-generation sequencing (NGS), STR, SNP analysis, and karyomapping. The integration of PGT-M with IVF helps prevent genetic diseases at the embryo stage, delivering long-term benefits for the health of future generations.

Within the framework of the session, Dr. Vinh also highlighted Eurofins GENTIS’s testing capacity and internationally standardized laboratory system, featuring the Illumina MiSeq NGS platform and specialized analysis software BlueFuse. Notably, the achievement of CAP accreditation for PGT testing serves as strong evidence of quality, reliability, and standardization across the entire genetic testing workflow at GENTIS.

Beyond introducing genetic testing services and modern laboratory infrastructure, Dr. Nguyen Quang Vinh also directly addressed professional questions from Phenikaa Hospital’s experts and physicians, helping clarify practical issues related to the application of genetic testing in assisted reproduction. Physicians at Phenikaa Hospital highly appreciated the professional insights, real-world data, and testing solutions provided by Eurofins GENTIS, considering them an important foundation for improving treatment outcomes and the quality of care for IVF patients.

The professional exchange between Eurofins GENTIS and Phenikaa Hospital not only held academic value but also opened up directions for sustainable collaboration in training, clinical consultation, and the implementation of advanced genetic testing solutions. Through close cooperation, both parties expect to contribute to improving IVF treatment effectiveness, reducing the psychological and financial burden on patients, and delivering meaningful value to the community in the journey toward fulfilling the dream of having healthy children.

[content_more] => [meta_title] => Eurofins GENTIS and Phenikaa hospital strengthen professional exchange on preimplantation genetic te [meta_description] => In recent years, alongside in vitro fertilization (IVF), preimplantation genetic testing (PGT) solutions have increasingly been recognized as a key factor in improving success rates, minimizing risks, and working toward the goal of delivering healthy babi [meta_keyword] => GENTIS,Phenikaa [thumbnail_alt] => [post_id] => 1405 [category_id] => 15 ) [4] => stdClass Object ( [id] => 1404 [id_crawler] => [category_product] => NULL [thumbnail] => rabbit_media-4214.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2026-01-23 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2026-01-23 10:43:46 [updated_time] => 2026-01-30 13:27:57 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Trends-and-applications-of-AI-and-omics-data-in-genetic-testing-and-reproductive-genetic-counseling [title] => Trends and applications of AI and omics data in genetic testing and reproductive genetic counseling [description] => In recent years, artificial intelligence (AI) has emerged as one of the key driving forces behind the technological revolution across many fields, especially healthcare. From medical imaging diagnostics and chronic disease management to drug research and development, AI has demonstrated its pivotal role in improving treatment effectiveness and personalizing healthcare. In the field of genetics and assisted reproduction, the integration of AI, bioinformatics, and Omics data is expected to create major breakthroughs, significantly enhancing the quality of screening, diagnosis, and genetic counseling. [content] =>

AI and omics data – The foundation of precision medicine
The rapid development of next-generation sequencing (NGS), mass spectrometry technologies, along with the increasing capacity for collecting and storing large-scale clinical data, has generated an enormous volume of information in medical genetics. Omics data—including genomics, transcriptomics, proteomics (proteins and post-translational modifications), metabolomics (metabolites and hormones), together with bioinformatics and AI—provide a comprehensive reflection of biological characteristics at the molecular level. However, analyzing and effectively exploiting these datasets poses a major challenge if relying solely on traditional methods.

Dr. Pham Dinh Minh (R&D Director, Eurofins GENTIS) presenting at the Symposium on Reproductive Genetics and PGT

With its machine learning capabilities and multidimensional data analysis, AI enables rapid and accurate processing of complex Omics datasets, thereby uncovering potential relationships among genetic factors, clinical data, and disease risks. In assisted reproduction, this opens up opportunities to improve embryo screening quality, predict implantation potential, and provide more scientific and personalized genetic risk counseling for couples.

Eurofins GENTIS pioneers the application of AI in reproductive genetics
According to Dr. Pham Dinh Minh (R&D Director of Eurofins GENTIS) at the Symposium on Reproductive Genetics and PGT, in recent years Eurofins GENTIS has focused on developing information technology platforms and AI applications integrated with Omics data to support genetic screening, counseling, and management of hereditary diseases. These solutions not only provide professional support for hospitals and partners but also strengthen the connection between Eurofins GENTIS, clinicians, healthcare facilities, and patients, contributing to improved user experience and healthcare service quality.

In the field of genetic analysis, Eurofins GENTIS has been researching and developing various bioinformatics tools to support the application of AI in studying the molecular mechanisms of fertilization, embryo development, and factors affecting infertility and subfertility. These studies aim to improve the success rates of in vitro fertilization (IVF) and to personalize treatment for each patient in the future.

PGT-AI – A new approach to embryo selection
One of the greatest challenges in IVF today is how to increase pregnancy rates and the likelihood of delivering healthy babies after embryo transfer. According to Dr. Pham Dinh Minh, the embryo is the decisive factor determining the success of an IVF cycle. Selecting the best embryo not only affects implantation rates but also has long-term implications for the child’s future health.

In this context, the application of artificial intelligence in preimplantation genetic testing (PGT-AI) is considered a highly promising trend. PGT-AI goes beyond the assessment of chromosomal abnormalities in embryos and aims to select the “best embryo among good embryos” from a genetic perspective.

Eurofins GENTIS Is researching the application of AI to predict embryo transfer success

Currently, Eurofins GENTIS is conducting pilot studies on applying AI to predict the success potential of embryo transfer. By analyzing the genetic data of embryos in combination with maternal clinical factors, AI can help identify relationships between embryos and their compatibility with the uterine environment. This enables clinicians to make optimal embryo selection decisions, thereby improving implantation rates and overall IVF success.

By integrating maternal clinical data and expanding the analysis of embryonic genetic data within PGT-AI, the research team at Eurofins GENTIS is developing screening and predictive models to identify healthy embryos with high implantation potential. This is regarded as an important step toward personalized counseling and assisted reproductive treatment.

Applications of AI in NIPT and newborn screening

In addition to IVF and PGT-AI, AI is also being strongly applied by Eurofins GENTIS in the fields of prenatal and newborn screening. In non-invasive prenatal testing (NIPT), Eurofins GENTIS collaborates with the University of Engineering and Technology – Vietnam National University, Hanoi, to develop bioinformatics algorithms that expand the detection spectrum of genetic variants. As a result, the sensitivity, accuracy, and specificity of NIPT have been significantly improved, contributing to higher-quality fetal anomaly screening.

Eurofins GENTIS Is researching and applying AI and Information technology in newborn screening

For newborn screening, Eurofins GENTIS is developing AI-integrated software solutions to enhance the detection of complex metabolic disorders based on mass spectrometry data. From these datasets, algorithms are built to support rapid and accurate early prediction and diagnosis of genetic diseases related to metabolic disorders in newborns.

Notably, in the process of reporting results, Eurofins GENTIS has integrated information technology and AI to interpret testing data, helping clinicians and families more easily access disease-related information, understand risks, and determine appropriate treatment directions for infants.

The application of AI and Omics data in genetic testing and counseling is ushering in a new era for assisted reproduction and precision medicine. With ongoing research and real-world applications, Eurofins GENTIS demonstrates its pioneering role in bringing advanced technologies into reproductive healthcare services in Vietnam.

In the future, as datasets become more comprehensive and AI algorithms more refined, AI-based genetic solutions are expected to support clinicians in making more accurate decisions, optimizing treatment outcomes, creating opportunities for parenthood for many infertile couples, and contributing to sustainable improvements in population health.

[content_more] => [meta_title] => Trends and applications of AI and omics data in genetic testing and reproductive genetic counseling [meta_description] => In recent years, artificial intelligence (AI) has emerged as one of the key driving forces behind the technological revolution across many fields, especially healthcare. From medical imaging diagnostics and chronic disease management to drug research and [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1404 [category_id] => 15 ) [5] => stdClass Object ( [id] => 1398 [id_crawler] => [category_product] => NULL [thumbnail] => 605764480_1275897227908799_5804145375518154194_n.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-12-29 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-29 08:29:14 [updated_time] => 2026-01-15 09:52:40 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Congratulations-on-the-successful-December-prenatal-class-The-journey-to-happy-motherhood-of-Andrology-and-Fertility-hospital-of-Hanoi [title] => Congratulations on the successful December prenatal class – The journey to happy motherhood of Andrology and Fertility hospital of Hanoi [description] => On the morning of December 27, 2025, at the 5th Floor Hall – Building A, Andrology and Fertility hospital of Hanoi, the program “Prenatal Class – The Journey to Happy Motherhood” was successfully held, leaving many deep emotions and meaningful values for all expectant mothers and their families in attendance. The program was not only a simple medical knowledge-sharing session but also a journey of spreading love, understanding, and strong faith for families preparing to welcome their little angels. [content] =>

Prenatal class – A strong foundation for the journey of motherhood

Pregnancy and childbirth are sacred journeys, yet they are also accompanied by many worries and concerns, especially for first-time mothers or families who have experienced the long and challenging journey of infertility. Understanding this, Hanoi Andrology and Fertility Hospital, in collaboration with the Happy Home Association, organized the Prenatal Class – The Journey to Happy Motherhood with the hope of providing expectant mothers with scientific knowledge, emotional stability, and the most comprehensive preparation before their delivery day.

From early morning, the hall welcomed a large number of expectant mothers and their families, creating a warm, intimate atmosphere filled with positive energy. The enthusiastic participation of families clearly reflected the strong demand for systematic prenatal education and the trust they place in the hospital’s medical team.

Experienced doctors accompanying Parents-to-be

The program was honored to have the direct participation and sharing of experienced obstetrics and gynecology specialists from Hanoi Andrology and Fertility Hospital:
Dr. Nguyen Thi Hong Nhung, Specialist in Obstetrics and Gynecology, and Dr. Dam Dinh Tam, Specialist in Obstetrics and Gynecology.

With solid professional expertise and years of experience accompanying thousands of childbirth cases, the doctors delivered practical, easy-to-understand, and highly relevant information. The class focused on key concerns such as physical changes during pregnancy, signs of labor, natural birth and cesarean section procedures, pain management during labor, postpartum care for both mother and baby, as well as psychological preparation for welcoming the newborn.

Beyond one-way knowledge sharing, the doctors devoted significant time to directly answering every question from expectant mothers and their families — from simple concerns about nutrition and safe exercise to deeper worries about the childbirth process — all were carefully listened to and thoroughly advised.

Providing official medical knowledge – Confidence for a safe delivery

One of the most outstanding values of the prenatal class was the provision of official medical knowledge based on professional guidelines and clinical practice. This helped expectant mothers avoid misleading and unverified information widely circulating on social media.

Through the class, mothers gained a better understanding of their own bodies, learned how to listen to changes during pregnancy, and recognized early signs that require medical attention. More importantly, with sufficient knowledge and strong psychological preparation, mothers felt much more confident and reassured when approaching childbirth — a sacred and unforgettable milestone in life.

Many participants shared that after the session, they felt more relaxed, less anxious, and more confident about the journey ahead. This is precisely the goal Hanoi Andrology and Fertility Hospital always strives for when organizing its regular prenatal classes.

A loving connection space for the whole family

Not only for expectant mothers, the prenatal class also created an opportunity for future fathers and family members to join, listen, and better understand the journey of pregnancy and childbirth. Family support is a powerful source of emotional strength, helping mothers feel more secure and happy.

The class atmosphere was open and friendly, where everyone could share their own stories, emotions, and experiences. This meaningful connection helped form a warm community where families prepared for parenthood with a proactive and positive mindset.

Eurofins GENTIS – Proud to be the accompanying sponsor

Contributing significantly to the success of the program, Eurofins GENTIS was honored to be the accompanying sponsor of the Prenatal Class – The Journey to Happy Motherhood. With the mission of providing high-quality testing solutions and healthcare services, Eurofins GENTIS continuously supports Vietnamese families in achieving safe and healthy pregnancies and childbirth.

Their companionship not only ensured a well-organized and meaningful program but also reflected a long-term commitment to maternal and child healthcare, especially during the prenatal stage — the foundation for a child’s comprehensive development in the future.

In the coming time, Eurofins GENTIS will continue accompanying the regular prenatal classes of Hanoi Andrology and Fertility Hospital, contributing to the best possible physical and emotional preparation for expectant mothers before childbirth. Because Eurofins GENTIS understands that each class is not just a knowledge-sharing session, but also a meaningful milestone that builds mothers’ confidence, strengthens family bonds, and makes the journey of parenthood gentler and happier.

The Prenatal Class – The Journey to Happy Motherhood on December 27, 2025 concluded in a warm atmosphere filled with joy and trust. The success of the program once again affirms the continuous efforts of Hanoi Andrology and Fertility Hospital in providing comprehensive care for families, along with the valuable support of partners such as Eurofins GENTIS.

We wish all expectant mothers good health, peace of mind, a fulfilling pregnancy, and a smooth, gentle delivery. May all families soon welcome their beloved babies, opening a new chapter filled with happiness and love.

[content_more] => [meta_title] => Congratulations on the successful December prenatal class – The journey to happy motherhood of Andro [meta_description] => On the morning of December 27, 2025, at the 5th Floor Hall – Building A, Andrology and Fertility hospital of Hanoi, the program “Prenatal Class – The Journey to Happy Motherhood” was successfully held, leaving many deep emotions and meaningful values for [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1398 [category_id] => 15 ) [6] => stdClass Object ( [id] => 1397 [id_crawler] => [category_product] => NULL [thumbnail] => 299d08137c20f37eaa31.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-12-26 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-26 15:55:42 [updated_time] => 2026-01-14 15:50:20 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-&-andrology-and-fertility-hospital-of-Hanoi-announce-research-on-recurrent-pregnancy-loss-The-role-of-multigene-sequencing-in-genetic-screening-and-counseling [title] => Eurofins GENTIS & andrology and fertility hospital of Hanoi announce research on recurrent pregnancy loss: The role of multigene sequencing in genetic screening and counseling [description] => Recently, the scientific study entitled “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” conducted by Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility, was officially published in Issue No. 197 of the Journal of Medical Research. [content] =>

The study was conducted with the objective of investigating the spectrum of genetic variants detected by FertiScan™ (a test designed to identify genetic abnormalities associated with female infertility and recurrent pregnancy loss) in women with a history of recurrent miscarriage.

The study population consisted of 20 infertile women with a history of recurrent pregnancy loss (RPL). RPL was defined as two or more consecutive spontaneous miscarriages before 20 weeks of gestation at the Hanoi Hospital of Andrology and Infertility from May to August 2023.

The study indicates that recurrent miscarriage and repeated fetal loss are common challenges in assisted reproductive practice, affecting approximately 1–5% of women of reproductive age. In addition to uterine anatomical, endocrine, immunohematological, and infectious causes, genetic factors play an important role but are not easily detected by routine testing. The cause of miscarriage remains unknown in more than 50% of these cases.

Karyotype analysis and microarray testing are useful for identifying chromosomal numerical and structural abnormalities, but they remain limited in detecting single-gene causes related to oocyte development, meiosis, implantation, and early embryonic viability. Therefore, targeted molecular genetic approaches are receiving increasing attention.

In recent years, next-generation sequencing (NGS) panels have enabled simultaneous analysis of multiple genes related to female reproduction, expanding the ability to identify genetic etiologies in patients with recurrent miscarriage and fetal loss. Among these, the FertiScan™ Global Female Infertility Panel is a representative tool, covering more than 70 genes involved in key pathogenic mechanisms including premature ovarian failure and ovarian dysfunction, ovarian dysgenesis, defects in oocyte maturation, abnormal oocyte–zona pellucida–fertilization interactions, genes affecting implantation and endometrial signaling, as well as DNA repair genes associated with early embryonic lethality.

This approach not only increases the detection rate of clinically significant genetic variants but also supports personalized counseling and intervention strategies, including partner testing in autosomal recessive disorders, indications for PGT-M or PGT-SR, and prenatal genetic screening when appropriate.

In Vietnam, data on the prevalence of genetic variants in women with unexplained recurrent pregnancy loss remain limited. This gap restricts optimal prognostic counseling and personalized treatment, particularly in cases with normal karyotype results but persistent pregnancy loss.

The implementation of specialized targeted NGS panels such as FertiScan™ provides value in identifying subsets of patients carrying pathogenic or likely pathogenic variants truly associated with reproductive biological mechanisms, and in documenting variants of uncertain significance (VUS) within the Vietnamese population in order to gradually standardize variant interpretation according to the classification guidelines of the American College of Medical Genetics and Genomics (ACMG). FertiScan™ results are interpreted following ACMG/AMP (American College of Medical Genetics and Genomics/Association for Molecular Pathology) variant classification guidelines, including pathogenic (P), likely pathogenic (LP), variant of uncertain significance (VUS), and benign/likely benign. Variant classification is always considered within the specific clinical and family context to ensure individual appropriateness.

From an application perspective, FertiScan™ enhances the detection of monogenic causes in patients with recurrent pregnancy loss, particularly in cases without chromosomal abnormalities identified by karyotype or microarray. The test also supports personalized genetic counseling, including partner testing in recessive genetic conditions, recommendations for PGT-M/PGT-SR, and the development of appropriate prenatal or preconception screening plans. Furthermore, FertiScan™ demonstrates strong potential for application in genetic epidemiology research in Vietnam, contributing to the establishment of population-based variant databases, thereby improving the accuracy of variant interpretation and the quality of diagnosis, counseling, and future interventions.

These results highlight the importance of systematically integrating genetic testing into the evaluation of recurrent miscarriage and fetal loss, with multigene testing positioned within structured pre- and post-test counseling and long-term follow-up strategies.

With the mission of “Enhancing the intellectual and physical well-being of the Vietnamese people,” Eurofins GENTIS continues its collaboration with the Hanoi Hospital of Andrology and Infertility to implement high-value medical research and to further develop a comprehensive ecosystem of advanced genetic testing. Through these efforts, Eurofins GENTIS contributes to delivering modern healthcare solutions and supporting medical professionals in improving reproductive healthcare for the community.

[content_more] => [meta_title] => Eurofins GENTIS & andrology and fertility hospital of Hanoi announce research on recurrent pregnancy [meta_description] => Recently, the scientific study entitled “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” conducted by Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility, was officially published in Issue N [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1397 [category_id] => 15 ) [7] => stdClass Object ( [id] => 1396 [id_crawler] => [category_product] => NULL [thumbnail] => 06f14a7e3e4db113e85c.jpg [album] => [url_video] => [is_status] => 1 [is_featured] => 0 [is_form] => 0 [displayed_time] => 2025-12-26 [program] => 0 [number] => 1 [viewed] => 0 [type] => [type_career] => [level] => [address] => [address_career] => [expiration_time] => 0000-00-00 [created_time] => 2025-12-26 08:41:18 [updated_time] => 2026-01-14 15:41:21 [files] => [salary] => [time] => [created_by] => 63 [is_table_content] => 1 [language_code] => en [slug] => Eurofins-GENTIS-&-Andrology-and-fertility-hospital-of-Hanoi-publish-research-findings-on-recurrent-pregnancy-loss-in-the-journal-of-medical-research [title] => Eurofins GENTIS & Andrology and fertility hospital of Hanoi publish research findings on recurrent pregnancy loss in the journal of medical research [description] => Recently, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility officially published the results of their scientific study evaluating the role of multigene sequencing (NGS) — specifically the FertiScan™ panel — in identifying genetic causes in women with a history of recurrent pregnancy loss (RPL). [content] =>

The research findings were presented in the scientific article entitled: “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” which was published in Journal of Medical Research, Issue No. 197, December 2025 — a prestigious journal featuring original research and review articles in basic medicine, clinical medicine, preventive medicine, public health, and medical sociology, aimed at advancing medical knowledge and practice.

The study was conducted on 20 infertile patients with a history of recurrent pregnancy loss at the Hanoi Hospital of Andrology and Infertility between May and August 2023. According to experts, recurrent miscarriage and fetal loss represent a major challenge in assisted reproduction, affecting approximately 1–5% of women of reproductive age.

In recent years, next-generation sequencing (NGS) panels have enabled simultaneous analysis of multiple genes related to female reproduction, significantly expanding the ability to identify genetic etiologies in patients with recurrent miscarriage and fetal loss.

Among these tools, the FertiScan™ Global Female Infertility Panel is particularly comprehensive, covering more than 70 genes involved in key pathogenic mechanisms, including: Premature ovarian failure and ovarian dysfunction. Ovarian dysgenesis. Oocyte maturation defects. Abnormal oocyte–zona pellucida–fertilization interactions. Genes affecting implantation and endometrial signaling. DNA repair genes associated with early embryonic lethality

In this study, researchers used the FertiScan™ Global Female Infertility Panel (70 genes) based on NGS technology to simultaneously examine coding regions and splice sites of the target genes.

Among the 20 patients, 12 cases (60%) carried ≥ 1 reproduction-related genetic variant, including: 4 patients harboring pathogenic or likely pathogenic variants (P/LP). Predominantly in the heterozygous state of autosomal recessive disorders.

A substantial proportion of detected variants were classified as variants of uncertain significance (VUS). Notably, variants were identified in genes with well-established biological roles, such as CEP250, TACR3, NOBOX, ZP1, and others.

The FertiScan™ test which identifies genetic causes of infertility and rare hereditary abnormalities associated with female infertility and recurrent miscarriage, as well as evaluates male reproductive health — significantly enhances the detection of monogenic causes in patients with RPL, particularly in cases without chromosomal abnormalities detected by karyotyping or microarray analysis.

The test also supports personalized genetic counseling, including: Partner testing in autosomal recessive conditions. Indications for PGT-M (preimplantation genetic testing for monogenic diseases). PGT-SR (preimplantation genetic testing for structural chromosomal rearrangements). Development of tailored prenatal and preconception screening strategies

Beyond its clinical value, FertiScan™ demonstrates strong potential in genetic epidemiology research in Vietnam, contributing to the establishment of population-specific variant databases and thereby improving variant interpretation, diagnostic accuracy, counseling, and future clinical interventions.

Researchers concluded that multigene testing such as FertiScan™ significantly improves the detection of underlying causes in unexplained RPL cases, particularly when integrated into comprehensive pre- and post-test counseling and long-term follow-up.

Sharing insights on the study, Dr. Pham Dinh Minh, R&D Director of Eurofins GENTIS and co-author of the publication, stated:“Publishing in the Journal of Medical Research is a long journey — from idea generation, study implementation, data analysis, manuscript preparation, submission, to rigorous peer review. Beyond scientific merit, the research must demonstrate strict methodological rigor and data integrity. We spent more than three months collecting data and over two years completing the project. The publication of this work is a source of pride for our team and opens new avenues for research in infertile women with recurrent pregnancy loss, helping realize the dream of parenthood for many couples and highlighting the immense potential of genetic applications in reproductive medicine in Vietnam.”

Through systematically conducted research and publication in prestigious scientific journals, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility continue to reaffirm their joint commitment to advancing genetic research and its integration into clinical practice — contributing to improved diagnostic and treatment quality in assisted reproduction across Vietnam.

[content_more] => [meta_title] => Eurofins GENTIS & Andrology and fertility hospital of Hanoi publish research findings on recurrent p [meta_description] => Recently, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility officially published the results of their scientific study evaluating the role of multigene sequencing (NGS) — specifically the FertiScan™ panel — in identifying genetic causes [meta_keyword] => GENTIS [thumbnail_alt] => [post_id] => 1396 [category_id] => 15 ) )

Eurofins GENTIS launches PGT-FAST – Embryo genetic screening solution with outstanding turnaround time

In recent years, advancements in assisted reproductive technologies have provided the opportunity for millions of couples worldwide to become parents. However, beyond creating embryos through in vitro fertilization (IVF), selecting embryos with good genetic quality remains a crucial factor in achieving successful pregnancies. Numerous studies have shown that chromosomal abnormalities in embryos are among the common causes of implantation failure, early miscarriage, or genetic syndromes in children after birth. Therefore, preimplantation genetic testing (PGT) has become increasingly important in modern IVF procedures. To support fertility centers in optimizing embryo selection, Eurofins GENTIS has launched a new test, PGT-FAST – an embryo genetic screening solution with the outstanding advantage of delivering results in just 15 hours.

Eurofins GENTIS updates PGT-FAST and GEN28 tests at Hanoi General Hospital IVF center

Recently, a delegation of experts from Eurofins GENTIS, led by Dr. Nguyen Quang Vinh (Director of Eurofins GENTIS Testing Center), held a professional working session with the doctors and nurses of the Hanoi General Hospital Assisted Reproduction Center. This collaboration aims to update the latest advances in genetic testing, thereby contributing to improved treatment outcomes for families facing infertility. The session also opened opportunities for academic exchange and laid the groundwork for deeper cooperation between the two units in the future.

Summary of 5 hereditary cancer testing packages at Eurofins GENTIS

Cancer is one of the leading causes of death worldwide. Numerous studies indicate that 5–10% of cancer cases are associated with hereditary factors, resulting from gene mutations that can be passed down from one generation to the next. Hereditary cancer testing helps identify risks early, enabling the development of appropriate monitoring, prevention, and medical intervention strategies.

Eurofins GENTIS and Phenikaa hospital strengthen professional exchange on preimplantation genetic testing

In recent years, alongside in vitro fertilization (IVF), preimplantation genetic testing (PGT) solutions have increasingly been recognized as a key factor in improving success rates, minimizing risks, and working toward the goal of delivering healthy babies. Scientifically guided embryo selection plays a crucial role in helping clinicians and patients make safer and more effective decisions in each treatment cycle.

Trends and applications of AI and omics data in genetic testing and reproductive genetic counseling

In recent years, artificial intelligence (AI) has emerged as one of the key driving forces behind the technological revolution across many fields, especially healthcare. From medical imaging diagnostics and chronic disease management to drug research and development, AI has demonstrated its pivotal role in improving treatment effectiveness and personalizing healthcare. In the field of genetics and assisted reproduction, the integration of AI, bioinformatics, and Omics data is expected to create major breakthroughs, significantly enhancing the quality of screening, diagnosis, and genetic counseling.

Congratulations on the successful December prenatal class – The journey to happy motherhood of Andrology and Fertility hospital of Hanoi

On the morning of December 27, 2025, at the 5th Floor Hall – Building A, Andrology and Fertility hospital of Hanoi, the program “Prenatal Class – The Journey to Happy Motherhood” was successfully held, leaving many deep emotions and meaningful values for all expectant mothers and their families in attendance. The program was not only a simple medical knowledge-sharing session but also a journey of spreading love, understanding, and strong faith for families preparing to welcome their little angels.

Eurofins GENTIS & andrology and fertility hospital of Hanoi announce research on recurrent pregnancy loss: The role of multigene sequencing in genetic screening and counseling

Recently, the scientific study entitled “Recurrent Pregnancy Loss: The Role of Multigene Sequencing in Genetic Screening and Counseling,” conducted by Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility, was officially published in Issue No. 197 of the Journal of Medical Research.

Eurofins GENTIS & Andrology and fertility hospital of Hanoi publish research findings on recurrent pregnancy loss in the journal of medical research

Recently, Eurofins GENTIS and the Hanoi Hospital of Andrology and Infertility officially published the results of their scientific study evaluating the role of multigene sequencing (NGS) — specifically the FertiScan™ panel — in identifying genetic causes in women with a history of recurrent pregnancy loss (RPL).